Tatiana Hurtado de Mendoza, PhD, is the first author of the study and assistant project scientist at UC San Diego and Moores Cancer Center.
Andrew Lowy, MD, is the co-corresponding author of the study, professor of surgery at UC San Diego School of Medicine and chief of the Division of Surgical Oncology at Moores Cancer Center at UC San Diego Health.
In animal models, tumor-penetrating therapy allows chemotherapy drugs to be delivered deeper inside tumor tissue, increasing effectiveness
Every 12 minutes, someone in the United States dies of pancreatic cancer, which is often diagnosed late, spreads rapidly and has a five-year survival rate at approximately 10 percent. Treatment may involve radiation, surgery and chemotherapy, though often the cancer becomes resistant to drugs.
Researchers at University of California San Diego School of Medicine and Moores Cancer Center, in collaboration with Sanford-Burnham-Prebys Medical Discovery Institute and Columbia University, demonstrated that a new tumor-penetrating therapy, tested in animal models, may enhance the effects of chemotherapy, reduce metastasis and increase survival.
The study, published online March 9, 2021 in Nature Communications, showed how a tumor-targeting peptide, called iRGD, can sneak inside the armor that the tumor built to protect itself and use the fibrous tissue as a highway to reach deeper inside, destroying the tumor from within.
The pancreas is a large gland located behind the stomach. It makes enzymes that aid digestion and hormones that regulate blood-sugar levels. Pancreatic ductal adenocarcinoma (PDAC) is a subtype of pancreatic cancer that is highly drug-resistant due, in part, by the hard shell-like outer layer surrounding the tumor.
“This type of tumor is made up of a dense fibrous tissue that acts as a barrier to drugs trying to get through. Many drugs can reach the vessels of the tumor, but they are not able to get deep into the tissue, making treatment less effective, and that is one reason why this type of cancer is so challenging to treat,” said Tatiana Hurtado de Mendoza, PhD, first author of the study and assistant project scientist at UC San Diego School of Medicine and Moores Cancer Center.
“Our study found that the tumor-penetrating peptide iRGD is able to use this fibrous network to deliver chemotherapy drugs deep into the tumor and be more effective.”
The research team examined the microenvironment of PDAC tumors in a mouse model. They found that after targeting the tumor blood vessels, iRGD binds to high levels of ?5 integrin, a protein produced by cells known as carcinoma-associated fibroblasts (CAFs) that produce much of the tumor’s protective fibrous cover.
“We were able to closely replicate human disease in our mouse model and found that when iRGD was injected with chemotherapy in mice with high levels of ?5 integrin, there was a significant increase in survival and a reduction in the cancer spreading to other organs in the body compared to chemotherapy alone. This could be a powerful treatment strategy to target aggressive pancreatic cancer,” said Andrew Lowy, MD, co-corresponding author of the study, professor of surgery at UC San Diego School of Medicine and chief of the Division of Surgical Oncology at Moores Cancer Center at UC San Diego Health.
“What is also exciting about this finding is the iRGD therapy did not produce any additional side effects. This is critically important when considering treatments for patients.”
The researchers said next steps include a national human clinical trial. They estimate the trial could begin in one year.
“The knowledge gained from our study has the potential to be directly applied to patient care. We also believe that the levels of ?5 integrin within a pancreatic cancer could tell us which patients would benefit the most from iRGD-combination therapy,” said Lowy.
Original Article: Therapy Sneaks into Hard Layer of Pancreatic Cancer Tumor and Destroys it From Within
More from: University of California San Diego School of Medicine | University of California San Diego | Sanford Burnham Prebys Medical Discovery Institute | Columbia University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Pancreatic cancer
- Pregnant with pancreatic cancer: How a NJ mom endures a devastating diagnosis
Months before she was due to give birth to her second daughter last year, Jaclyn Lin was eventually diagnosed with Stage 4 pancreatic cancer.
- Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer
Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially ...
- QW cyclist set to break 100k raised this year for pancreatic cancer research
Quinte West resident John Barry has ridden 20,000 KM's over the past seven years and raised $95,000 toward pancreatic cancer research by participating in the '7 Days' fundraiser. This year, Barry will ...
- FN Media Group: Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
FN Media Group News Commentary PALM BEACH, Fla., May 9, 2024 /PRNewswire/ -- The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of ...
- Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
PALM BEACH, Fla., May 9, 2024 /PRNewswire/ -- The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society predicts ...
Go deeper with Google Headlines on:
Pancreatic cancer
[google_news title=”” keyword=”pancreatic cancer” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Tumor-penetrating therapy
- What's keeping the U.S. from allowing better sunscreens?
A 1938 law classifies sunscreens as drugs, rather than cosmetics. That's delayed the rollout of products that more effectively block ultraviolet rays that cause skin cancer.
- Kexing Biopharm Teams Up with Qingfeng Pharma for the Global Market on Olaparib Tablets
Kexing Biopharm recently took an important step forward in cancer therapy. Kexing Biopharm signed a cooperation agreement with Kerui Pharma, a subsidiary of Qingfeng Pharmaceutical Group (hereinafter ...
- Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024Projected available cash to fund planned operations into early 2026 ...
- Merck's endometrial cancer therapy fails trial
Merck said on Thursday its therapy did not meet the main goal of disease-free survival in certain patients with endometrial cancer during a late-stage trial.
- Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer
Keytruda is already approved in patients with endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). The PD-1 inhibitor picked up that nod in 2022 ...
Go deeper with Google Headlines on:
Tumor-penetrating therapy
[google_news title=”” keyword=”tumor-penetrating therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
[embedyt] https://www.youtube.com/embed?listType=playlist&list=PL0UjJ07OSXC83oV409r1yRju8-ihA1InJ&layout=gallery[/embedyt]